Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Neuren Pharmaceuticals Limited ( (AU:NEU) ) has provided an announcement.
Neuren Pharmaceuticals Limited announced a daily update on its ongoing on-market buy-back program, revealing that a total of 31,664 ordinary fully paid securities were bought back on the previous day. This buy-back initiative, which commenced on November 14, 2024, is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$31.40 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of drugs for neurological disorders. The company is primarily engaged in creating therapies for conditions such as Rett syndrome and Fragile X syndrome, targeting niche markets within the broader healthcare sector.
Average Trading Volume: 727,923
Technical Sentiment Signal: Buy
Current Market Cap: A$1.74B
Find detailed analytics on NEU stock on TipRanks’ Stock Analysis page.